Weekly Roundup: April 3–9, 2020

More from:

This roundup contains a collection of the posts published on the Forum during the week of April 3–9, 2020

SEC–Exempt Offerings

Executive Compensation Programs & COVID-19

COVID-19 as a Material Adverse Effect (MAC) Under M&A and Financing Agreements

Federal Forum Selection Bylaws for Securities Act Claims

The Atmosphere for Climate-Change Disclosure

Rewriting the Poison Pill Prescription: Consider Active Defenses During COVID-19

Postponing/Adjourning Annual Meetings Following COVID-19

Federal Forum Provision Possible Impact on D&O Insurance

Thoughts for Boards of Directors in the COVID19 Crisis

Fiduciary Duties During a Time of Volatility

ESG Disclosures and Litigation Concerns

Corp Fin Disclosure Guidance: Topic No. 9 Coronavirus

Director Oversight in the Context of COVID-19

Purchasing Portfolio Company Debt—Threshold Issues for Private Equity Sponsors

Proactively Adopting a Poison Pill in Response to the COVID-19 Crisis

Accounting Class Action Filings and Settlements: 2019 Review and Analysis

Annual General Meetings & COVID-19

Are Corporate Payouts Abnormally High in the 2000s?

A Turn Back to “Poison Pills” in Response to the Coronavirus Pandemic

More from:
Both comments and trackbacks are currently closed.